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Abstract  
 
Background: To investigate metabolic changes associated with second-line 
antiretroviral therapy (ART) following virological failure of first-line ART.  
 
Methods: SECOND-LINE was an open-label randomized controlled trial. Participants 
were randomized 1:1 to receive ritonavir-boosted lopinavir (LPV/r) with 2-3 
nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI-group) or raltegravir 
(RAL-group) Two hundred and ten participants had a dual energy X-ray 
absorptiometry (DXA)-scan at baseline, week 48 and 96. We categorized participants 
according to second-line ART backbone: 1. thymidine analogue (ta-
NRTI)+lamivudine/emtricitabine (3[F]TC) [ta-NRTI group]; 2. tenofovir (TDF)+3[F]TC 
[TDF group]; 3. TDF+ta-NRTI+/-3[F]TC [TDF+ta-NRTI group]; 4. RAL. Changes in fasted 
total cholesterol, LDL-cholesterol, HDL-c, TC/HDL-cholesterol ratio, triglycerides and 
glucose from baseline to week 96 were examined. We explored the association 
between metabolic and DXA-assessed soft-tissue changes. Linear regression 
methods were used.  
 
Results: We analyzed 454 participants. Participants in RAL group had greater TC 
increases TC (adjusted mean difference (aMD)=0.65, 95%CI 0.33, 0.96), LDL-c 
(aMD=0.38, 95%CI 0.15, 0.61) and glucose (aMD = 0.47, 95%CI -0.01, 0.92) compared 
to TDF group, and had greater increases in TC (aMD=0.65, 95%CI 0.28, 1.03), HDL-c 
(aMD=0.12, 95%CI 0.02, 0.23) and LDL-c (aMD=0.41, 95%CI 0.13, 0.69;) compared to 
TDF+ta-NRTI group. TC/HDL ratio and triglycerides increased in all groups without 
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significant differences between groups. A 1kg increase in trunk fat mass was 
associated with an increase in TC. 
 
Conclusions: We observed metabolic changes of limited clinical significance in the 
relatively young population enrolled in this study. However, the metabolic changes 
observed may have greater clinical significance in older people living with HIV or 
those with concomitant cardiovascular risks. 
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Background   
Antiretroviral therapy (ART) has been associated with unfavourable changes in lipid 
parameters that increase cardiovascular risk. Some data also suggests an association 
between ART, particularly some protease inhibitors (PI), and impaired glucose 
tolerance (1, 2). Confusing the interpretation is the fact that lipid changes may not 
be a direct consequence of ART but rather signify a return to health induced by 
successful ART and associated weight gain, with increase in body fat driving 
metabolic changes as found in the general population. This is supported by studies 
indicating that weight increase is correlated with increased CD4 count (3). A recent 
dual energy X-ray absorptiometry (DXA) -scan substudy of ACTG 5257 showed that 
darunavir/ritonavir (DRV/r), atazanavir/ritonavir (ATV/r) and raltegravir (RAL) (all 
combined with tenofovir [TDF]/ emtricitabine[FTC]) were associated with the same 
degree of visceral fat accumulation(4). The SECOND-LINE DXA substudy showed that 
participants on lopinavir/ritonavir (r/LPV)+RAL and those on r/LPV+ 
nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) experienced similar 
increases in limb fat and total body and trunk fat mass over 48 weeks(5).  
 
Dyslipidemia has been reported to occur with use of thymidine analogue-NRTIs (ta-
NRTI) (zidovudine [AZT] and stavudine [d4T]). Other N(t)RTIs, including TDF, have 
shown milder effects on metabolic parameters in comparison to ta-NRTIs. (6-10) TDF 
has also been associated with less metabolic disturbance compared to 
abacavir/lamivudine (ABC/3TC)(11-13). The ACTG5206 study (10) suggested that TDF 
has an independent effect on improving lipid profiles. Non high density lipoprotein 
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cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) and total cholesterol 
(TC) decreased with addition of TDF to a stable ART regimen and a ‘rebound’ effect 
occurred when TDF was withdrawn. The lipid-lowering effect of TDF has been further 
supported by a recent RCT that found that addition of TDF/FTC to stable DRV/r or 
r/LPV regimens was associated with decreases in TC, LDL-c and HDL-c. (6) 
 
The integrase inhibitor class has been associated with more favourable lipid profiles 
compared to older ART classes. Switching from non-nucleoside reverse-transcriptase 
inhibitors (NNRTI) or PI- based therapy to RAL-based therapies has been associated 
with improvements in lipid profiles(14-16). There have been similar findings in 
studies involving treatment-naïve patients, comparing RAL with efavirenz (EFV) and 
PI regimens. Other integrase inhibitors including dolutegravir (DTG) and elvitegravir 
(EVG) have also demonstrated milder effects on lipid profiles when compared to 
drugs of other classes (17-19). However, an RCT comparing EVG/cobicistat/FTC/TDF 
to ATV/r + FTC/TDF found that EVG-based therapy was associated with greater 
increase in TC, but less increase in TG when compared to the ATV/r arm. (20) 
 
PIs have been consistently associated with lipid changes, in both monotherapy and 
switch studies (15, 16, 21, 22). The dyslipidemic effect of PIs is heavily influenced by 
the use of ritonavir as a booster, with regimens requiring higher dosage of ritonavir 
associated with greater dyslipidemia (23-25). Whilst NNRTIs have been less 
associated with lipid changes compared to other ART classes, studies have indicated 
that EFV has negative effects on lipid levels, whilst other NNRTIs including nevirapine 
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(NVP), etravine (ETV), rilpivirine (RPV) have been associated with beneficial increases 
in HDL-c and reductions in TC/HDL-c ratios (26-31). 
 
Insulin resistance associated with HIV may result from increased visceral adipose 
tissue, an indirect effect of long-term ART. (2). Changes in glucose, insulin and 
homeostatic model assessment insulin resistance (HOMA-IR) have been associated 
with changes in body mass index (BMI), lean body mass, limb and trunk fat (32). 
However the extent to which increased visceral adipose tissue is an ART-incited 
pathology rather than a ‘return-to-health’ is debated. The recent results of the DXA-
scan ACTG5257 substudy suggests that increased visceral adiposity is simply weight 
gain upon return-to-health as seen in the general population (4).  [ADD email 
suggestion]  
 
There is limited data investigating the metabolic changes associated with switches to 
boosted-PI containing second-line ART, following virological failure of World Health 
Organization (WHO)-recommended first-line ART. For first-line regimens, the new 
WHO recommendations (33) recommend EFV+TDF+ lamivudine or emtricitabine 
(3[F]TC) or Dolutegravir (DTG) + TDF/3[F]TC if EFV is found to be intolerable. For 
second-line regimens, WHO recommends boosted PI (LPV/r or ATV/r or DRV/r) + 
2N(t)RTIs or boosted PI + RAL as an alternative.  
 
Hypothesis 
We hypothesized that second-line PI-containing ART regimens combined with ta-
NRTIs would be associated with less favourable lipid profiles than regimens 
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containing TDF. We also hypothesised that the addition of TDF to taNRTI may have 
off-set some of the adverse lipid changes associated with taNRTI- regimens.  
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Methods 
Main Study Design  
SECOND-LINE was a 96-week open-label RCT including 541 HIV-1 infected adults at 
37 sites located in 15 countries, who had evidence of virological failure (defined as 
plasma HIV viral load>500 copies per mL on two consecutive [≥7 days apart] 
occasions). Participants were randomized (1:1) to receive LPV/r with either 2-
3N(t)RTI or RAL. N(t)RTI backbone selection was conducted by local investigators and 
was guided through pre-randomisation genotypic ART or by a simple algorithm (34).  
A subset of 210 patients in 8 sites from 5 countries (Argentina, India, Malaysia, 
Thailand, South Africa) underwent DXA scans to assess body composition changes at 
weeks 0 and 96 (5). 
 
Study participants and categorization  
For this post-hoc analysis participants were categorised in two ways (Figure 1):  
1. Participants were categorized purely on the basis of their second-line ART group 
(on-study groups)  
2. Participants were further categorized by both their first-line ART and their second-
line ART regimens (switch groups) (Figure 1).  
 
For the TDF + ta-NRTI on-study group, we combined participants who did (n=40/63 
[63%]) and did not (n=23/63 [37%]) receive 3[F]TC. This was done similarly for switch 
groups containing second-line TDF + ta-NRTI +/- 3[F]TC + r/LPV (22/30 [67%] 
switching from taNRTI to taNRTI + TDF did not receive 3[F]TC; 1/10 [10%] switching 
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from TDF to taNRTI + TDF did not receive 3[F]TC). Sensitivity analysis conducted to 
compare the metabolic outcomes between the two groups indicated no clinically or 
statistically significant differences between the groups.  
 
Participants who were on non-WHO recommended regimens, including non-3[F]TC 
and abacavir- and didanosine- containing regimens were excluded, as were those 
who switched regimens following initial second-line randomization.  Groups with a 
database cell size ≤11 were included in analysis but were excluded from our report 
as small numbers would preclude meaningful and reliable results.  
 
Data collection:  
Fasting serum lipids and glucose were measured (in mmol/L) during protocol-
specified visits at weeks 0, 4, 12, 24 and 48, 72 and 96. Homeostatic model 
assessment (HOMA) was calculated via electronic case report form. For the DXA-
substudy population, DXA-scans were conducted at baseline, week 48 and week 96 
on Lunar or Hologic scanners according to a standard protocol provided to all sites. 
(5) 
 
Statistical Analysis  
The primary study objective was to determine and compare the changes in TC/HDL-c 
ratio from baseline to week 96 by on-study groups. Secondary study objectives 
include descriptions of TC, HDL-c, LDL-c, triglyceride, glucose and HOMA changes 
from baseline to week 96 by on-study groups and switch groups.  
 
  
10 
Exploratory objectives included an assessment of the correlations between the 
changes in metabolic markers (TC/HDL-c, TC, HDL-c, LDL-c, triglyceride, glucose and 
HOMA) and changes in body composition (total fat mass, total lean mass, trunk fat 
mass, trunk lean mass, limb fat mass, limb lean mass, weight (all reported in kg), 
body mass index (BMI) (kg/m2),and waist/hip ratio) from baseline to week 96 in the 
subset of participants enrolled in the SECOND-LINE DXA-scan substudy.  
 
Analyses included all randomized participants who received at least one dose of 
study medication. Missing data was excluded from analysis. At baseline, there were 
4 participants (0.9%) with missing data for TC/HDL-c ratio, TC, HDL-c, triglyceride and 
glucose, 12 (2.6%) missing values for LDL-c and 5 (1.1%) missing values for HOMA. At 
week 96, there were 39 (8.6%) participants with missing data for TC/HDL-c ratio, TC, 
HDL-c, triglyceride, glucose and HOMA and 50 (11%) missing values for LDL-c.  
 
The primary endpoint of the SECOND-LINE study was the proportion of participants 
with a plasma HIV-1 RNA of less than 200 copies per ml at week 48 and has 
previously been reported (34). Sample size calculations were based on the primary 
endpoint. 
 
Linear regression methods were used to compare adjusted mean changes from 
baseline to week 96 in metabolic parameters between on-study group and switch 
group. Due to the non-randomised selection of the N(t)RTI regimens in the LPV/r + 2-
3 N(t)RTI arm, all analyses were adjusted a priori for measured confounders. These 
included age, sex, ethnicity, weight, BMI, systolic blood pressure, diastolic blood 
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pressure, waist/hip ratio, smoking, HIV disease stage, duration of HIV infection, CD4, 
CD8, (log) viral load, duration of first-line ART, alcohol consumption, estimated 
glomerular filtration rate (eGFR), hepatitis C antibody and use of lipid-lowering 
drugs. For the exploratory DXA component of our study, backwards-stepwise linear 
regression was used to assess the correlation between body composition change 
and metabolic change from baseline to week 96. Any body composition correlate 
with p<0.1 in univariate analysis was included in the multivariate model.  
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Results  
Of the 541 participants who formed the analysis population for the primary study, 
454 meet the criteria for analysis in this sub-study (Figure 1). Reason for exclusion 
included use of non-3[F]TC regimen in second-line, didanosine- or ABC-containing 
second-line regimen, second-line regimen switch at follow-up and use of a non-TDF- 
or taNRTI- containing first-line regimen (see figure 1). 
 
On-study group  
Compared to the overall study population, there were a greater proportion of 
women in the TDF+taNRTI group (60.3%) (Table 1). Compared to the overall 
population, there was a greater proportion of Africans (81.1% v 39.2%) in the taNRTI 
group, as well as lower median (IQR) baseline LDL-c (1.7 (1.4-2.2) vs 2.5 (1.9, 3.0)), 
duration of infection (2.7 years (2.0-5.1) vs 6.1 (3.7-8.7)), duration of pre-
randomisation cART (2.2 (1.5-4.3) vs 3.5 (2.0-5.7), baseline CD4 (64 (41-200) vs 199 
(101-296)) and baseline CD8 counts (536 (310-844) vs 800 (533.5-1095). Other 
variables were generally well balanced.  
 
TC/HDL ratio increased in all on-study groups, however there were no statistically 
significant differences between the groups (Figure 2). Similarly, triglyceride increased 
in all on-study groups, with no statistically significant differences between groups. 
Compared to participants receiving TDF+taNRTI, participants receiving second-line 
RAL experienced greater increases in TC (adjusted mean difference between groups 
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(aMD)=0.65, 95%CI [0.28, 1.03], p<0.001), LDL-c (aMD=0.41, 95%CI [0.13, 0.69], 
p=0.004) and HDL (aMD=0.12, 95%CI [0.02, 0.23], p=0.024). Participants receiving 
RAL also saw a greater increase in TC (aMD=0.65, 95%CI [0.33, 0.96], p<0.001), LDL-c 
(aMD=0.38, 95%CI [0.15, 0.61], p=0.001) and HOMA (aMD=1.37, 95%CI[0.01, 2.73] 
p=0.05) when compared to those receiving TDF, and a greater increase in glucose 
compared to those receiving TDF (aMD=0.47, 95%CI[-0.01, 0.92], p=0.05) and 
taNRTIs (aMD=0.89, 95%CI [0.09, 1.70], p=0.03). Participants receiving taNRTI 
experienced greater increases in HDL when compared to those receiving TDF (aMD= 
0.22, 95%CI [0.05, 0.39], p=0.012) and those receiving TDF+taNRTI (aMD=0.27, 
95%CI [0.01, 0.44], p=0.003).  
 
Switch group  
Compared to the overall study population, there was a greater proportion of males 
in the taNRTI to TDF group (66% vs 54%) and a greater proportion of females in the 
taNRTI to taNRTI+TDF group (62% vs 46%) (Table 2). There were a greater proportion 
of Africans in the TDF to taNRTI group (85%) compared to the overall population 
(39%). A greater proportion of the taNRTI to taNRTI+TDF group were overweight or 
obese (BMI>25) (50%), compared to the overall population (36%). For participants in 
the TDF to taNRTI group, there were lower median (IQR) baseline levels of LDL-c 
(median, IQR) (1.7 (1.3-2.1) vs 2.5 (1.9-3.0)), duration of HIV infection (3.1 years (2.0-
5.1) vs 6.1 (3.7-8.7)), duration of cART (2.2 (1.5-4.3) vs 3.5 (2.0-5.7)), baseline CD4 
(62 (35-176) vs 199 (101-296)) and baseline CD8 counts (495 (300-778) vs 800 
(533.5-1095)), when compared to the overall population.  Other variables were well 
balanced.  
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TC/HDL levels increased in all switch groups, however there were no significant 
differences between groups (Figure 3). Similarly, triglyceride increased in all switch 
groups, with no statistically significant differences between switch groups. 
 
Participants in the TDF to RAL switch group experienced greater increases in HDL 
(aMD=0.14, 95%CI [-0.01, 0.28], p=0.004) and TC (aMD=0.73, 95%CI [0.25, 1.21], 
p=0.003) when compared to those switching from taNRTI to TDF. Participants 
switching from TDF to RAL also experienced greater increases in HDL(aMD=0.22, 
95%CI [0.06, 0.37], p=0.006), TC (aMD=0.92, 95%CI [0.37, 1.47], p<0.01) and LDL-c 
(aMD=0.48, 95%CI [0.07, 0.89], p=0.02) when compared to those switching from 
taNRTI to TDF+taNRTI, and greater increase in HOMA (aMD=1.99, 95%CI [0.07, 3.90], 
p=0.04) when compared to those switching from taNRTI to RAL.  
 
Participants switching from taNRTI to RAL experienced greater increase in HDL 
(aMD=0.15, 95%CI [0.04, 0.27], p=0.009), TC (aMD=0.80, 95%CI [0.39, 1.21], 
p<0.001), LDL-c(aMD=0.55, [95%CI 0.24, 0.85], p<0.001) and HOMA (aMD=1.88, 
95%CI [0.10, 3.67], p=0.038) when compared to those switching from taNRTI to 
TDF+taNRTI. However, those switching from TDF to taNRTI experienced greater 
increase in HDL (aMD=0.19, [95%CI 0.02, 0.36], p=0.03) compared to taNRTI to RAL. 
Participants switched from taNRTI to RAL also saw greater increase in TC (aMD=0.61, 
95%CI [0.28, 0.94], p<0.001)), LDL-c (aMD=0.38, 95%CI [0.13, 0.62] p=0.003), glucose 
(aMD=0.56, 95%CI [0.08, 1.04], p=0.02) and HOMA (aMD=1.78, 95%CI [0.35, 3.2], 
p=0.015) when compared to those switched from taNRTI to TDF.  
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Participants switched from TDF to taNRTI experienced greater increases in HDL-c 
when compared to those switched from taNRTI to TDF+taNRTI (aMD=0.35, 
95%CI[0.15, 0.54], p<0.001) and taNRTI to TDF (aMD=0.27, 95%CI [0.09, 0.45], 
p=0.003).  
 
Exploratory Component Results  
The exploratory component of this study included the 210 patients enrolled in the 
DXA sub-study of the Second-Line study. (5) This population had a greater 
proportion of females (52%) compared to the primary study (46%). Multivariate 
analysis found no statistically significant correlations between body composition 
changes and baseline to week 96 changes in TC/HDL-c ratio, HDL-c, triglyceride, 
glucose and HOMA. A one-kilogram increase in trunk fat mass from baseline to week 
96 was associated with an increase in TC (adjusted mean change (aMC)=0.1mmol/L, 
95%CI [0.03, 0.17], p=0.009) and an increase in LDL-c (aMC=0.08 mmol/L, 95%CI 
[0.03, 0.14], p=0.002).  In univariate analysis, a one-kilogram increase in trunk fat 
mass from baseline to week 48 was not found to be significantly associated with 
changes in HDL-c (aMC= -0.01, 95%CI [-0.038, 0.012], p=0.3) or triglyceride levels 
(aMC=0.03, 95%CI [-0.06, 0.11], p=0.6).  
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Discussion  
In this study, second-line N(t)RTI-sparing ART with RAL+LPV/r was associated with 
greater increases in all cholesterol fractions, with a stable TC/HDL-c ratio and 
statistically significant but clinically insignificant glucose changes. These findings 
were consistent with those of the parent study which found the RAL group 
experienced increases in TC, HDL-c and LDL-c when compared to r/LPV + 2-3 N(t)RTI 
(34). Additionally, switches to second-line r/LPV + RAL regardless of first-line ART 
composition was associated with greater increases in all cholesterol fractions 
compared to switches to second-line N(t)RTI regimens.  
 
Contrary to our hypothesis, TDF-containing second-line ART regimens did not 
demonstrate a more favourable metabolic profile when compared to taNRTI-
containing regimens. The taNRTI group experienced greater beneficial HDL-c 
increases compared to the TDF and TDF+taNRTI groups, but there were no 
statistically significant differences in the TC/HDL-c ratio between the groups. As the 
population studied were individuals who had failed first-line ART, the regaining of 
virological control could be associated with an increase in HDL-c.    
 
A continuing challenge of investigating the metabolic effects in combination ART is 
the difficulty of distinguishing between the effects of individual drugs. Whilst our 
study found RAL to be associated with greater metabolic changes, prior studies have 
found that integrase inhibitors have minimal effects on metabolic profiles compared 
with N(t)RTIs and PIs (17, 19, 35). However, these studies have been conducted in 
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ART-naïve participants or switch studies with virological suppression and therefore 
the results are not directly comparable to those in our study of viremic participants. 
It is likely that the unfavourable metabolic profile associated with the N(t)RTI-sparing 
arm reflects the unopposed dyslipidemic effects of r/LPV rather than a specific 
contribution of RAL per se (22, 36, 37).  
 
The metabolic changes seen in this study could possibly be an effect of switching 
from NNRTI-based regimens to PI-based regimens. Ritonavir-boosted lopinavir has 
well known effects on serum lipid levels.  There is limited data from studies 
comparing NNRTI-based to PI-based therapy and most switch studies examine the 
metabolic effects of switching from a PI-based therapy to PI-sparing therapy. The 2-
LADY (38) and EARNEST (39) studies have explored efficacy and safety of second-line 
antiretroviral regimens. However they have not reported metabolic changes. As 
WHO recommends a switch from first-line NNRTI-based regimens to second-line PI-
based regimens with sequencing of the N(t)RTIs, our study provides valuable 
information regarding the expected metabolic effects of this common regimen 
switch (33).  
 
We have previously examined 10-year cardiovascular disease risk (CVD) in the 
SECOND-LINE DXA-subset population and found little change in CVD risk from 
baseline to week 48 despite increases in TC, LDL-c, triglyceride and TC/HDL-c ratio 
(5). The relatively young population and low prevalence of other known CVD risk 
factors such as smoking, hypertension and Type II Diabetes Mellitus indicate the 
ART-related lipid changes experienced during this study are unlikely to have great 
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clinical significance in this population. However, the described metabolic changes 
may have greater clinical impact later in this population and in older populations 
with greater prevalence of CVD risk factors and comorbidities.   
 
This study consisted of a relatively large and ethnically diverse population, with a 
high proportion of women. Sampling conducted in multiple sites across a variety of 
low- to middle- income countries allows our findings to be applicable to a broad 
population of people living with HIV worldwide. 
 
This study was limited by the fact that the selection of N(t)RTI regimen in the 2-3 
N(t)RTI + LPV/r was non-randomised. We adjusted for this by considering relevant 
confounders that may have influenced clinician choice. However, there may be other 
unknown confounders for which we are unable to adjust. The study took advantage 
of an opportunity presented by the conduct of a randomised controlled trial 
designed to assess the efficacy of an N(t)RTI-sparing ART as second-line therapy as 
opposed to a standard WHO-recommended N(t)RTI-containing therapy. As a 
consequence the study was not powered to detect specific metabolic differences 
between arms and therefore Type II errors may have been made. Other limitations 
include small data cells in some instances that were excluded due to unreliability. 
Additionally, some participants in the parent SECOND-LINE study were excluded due 
to non-WHO-recommended drugs (e.g. abacavir, didanosine) as it was believed they 
would not add valuable information for the purpose of this study.  
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Conclusion   
Our study explored the metabolic changes associated with WHO –recommended 
first-line to second-line N(t)RTI-containing or –sparing antiretroviral therapy switch. 
Contrary to our hypothesis, TDF-containing second-line regimens were not found to 
demonstrate more favourable lipid changes compared to taNRTI regimens. 
Management of serious non-AIDs events including dyslipidemia and consequently 
cardiovascular disease have become a crucial component of HIV management. Thus 
identifying and understanding the ART-induced metabolic changes is important. Our 
findings overall were expected and are in concordance with the findings of the 
parent SECOND-LINE study. Further research is required to examine the effects of 
switching from first-line to second-line WHO –recommended ART regimens, 
particularly as a substantial increase in the need for second-line drugs is predicted 
during the next few years (40).  
 
  
20 
 
Acknowledgements 
 
We acknowledge Hila Haskelberg at the Kirby Institute for her contribution.  
We thank the SECOND-LINE DXA-scan substudy committee, site investigators, site 
staff and participants for their contribution to this work. The Kirby Institute is 
affiliated with the Faculty of Medicine, University of New South Wales.  
 
Author Contributions 
This study was conceived by Amanda H. Yao, Cecilia L. Moore, Mark A. Boyd and 
David A. Cooper.  
All authors contributed to the statistical analysis plan.  
Amanda H. Yao and Cecilia L. Moore carried out statistical analysis.  
Amanda H. Yao wrote the first draft of the report with supervision from Cecilia L. 
Moore and Mark A. Boyd.  
All authors contributed to the final revision of the report submitted for peer-review.  
 
Funding 
This work was supported by Merck, AbbVie, The Foundation for AIDS Research and 
the Australian National Health & Medical Research Council. The views expressed in 
this publication do not necessarily represent the position of the Australian 
Government.  
  
21 
 
References  
 
 
1. Noor MA, Lo JC, Mulligan K, Schwarz J-M, Halvorsen RA, Schambelan M, et al. 
Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 
2001;15(7):F11-F8. 
2. Grunfeld C. Insulin resistance in HIV infection: drugs, host responses, or 
restoration to health? Top HIV Med. 2007;16(2):89-93. 
3. Huis't Veld D, Balestre E, Buyze J, Menten J, Jaquet A, Cooper DA, et al. 
Determinants of weight evolution among HIV-positive patients initiating 
antiretroviral treatment in low-resource settings. J Acquir Immune Defic Syndr. 
2015;70(2):146-54. 
4. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dube MP, et al. 
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: 
ACTG A5260s. Clin Infect Dis. 2016;62(7):853-62. 
5. Martin A, Moore CL, Mallon PWG, Hoy JF, Emery S, Belloso WH, et al. HIV 
Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + 
Raltegravir as Second-Line Antiretroviral Therapy. PLoS One. 2013;8(10):e77138. 
6. Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, et al. The lipid-
lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, 
placebo-controlled trial. Clin Infect Dis. 2015;61(3):403-8. 
7. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, et 
al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in 
antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201. 
8. Llibre JM, Domingo P, Palacios R, Santos J, Pérez-Elías MJ, Sánchez-de la Rosa 
R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients 
replacing stavudine with tenofovir. AIDS. 2006;20(10):1407-14. 
9. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. 
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz 
for HIV. N Engl J Med. 2006;354(3):251-60. 
10. Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et al. A 
pilot study to determine the impact on dyslipidemia of adding tenofovir to stable 
background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781. 
11. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir–
lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N Engl J Med. 
2009;361(23):2230-40. 
12. Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, et al. 96-
Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, 
in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 
2013;18(7):905-13. 
13. Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, et al. Abacavir 
does not affect circulating levels of inflammatory or coagulopathic biomarkers in 
suppressed HIV: a randomized clinical trial. AIDS. 2010;24(17):2657-63. 
  
22 
14. Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, et al. 
A randomized trial of Raltegravir replacement for protease inhibitor or non-
nucleoside reverse transcriptase inhibitor in HIV-infected women with 
lipohypertrophy. AIDS Patient Care STDS. 2012;26(9):532-40. 
15. Eron JJY, Benjamin, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, 
Workman C, et al. Switch to a raltegravir-based regimen versus continuation of a 
lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed 
viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised 
controlled trials. Lancet. 2010;375(9712):396-407. 
16. Martinez E, Larrousse M, Llibre JM, Gutierrez F, Saumoy M, Antela A, et al. 
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected 
patients: the SPIRAL study. AIDS. 2010;24(11):1697-707. 
17. Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, et al. 
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir 
versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and 
tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results 
of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 
2014;14(7):581-9. 
18. Pozniak A, Markowitz M, Mills A, Stellbrink H-J, Antela A, Domingo P, et al. 
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir 
versus continuation of non-nucleoside reverse transcriptase inhibitor with 
emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-
NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. 
Lancet Infect Dis. 2014;14(7):590-9. 
19. Molina J-M, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. 
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults 
with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, 
phase 3b study. Lancet HIV. 2015;2(4):e127-e36. 
20. Rockstroh JK, DeJesus E, Henry K, Molina J-M, Gathe J, Ramanathan S, et al. A 
Randomized, Double-Blind Comparison of Coformulated 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir 
Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 
Infection: Analysis of Week 96 Results. J Acquir Immune Defic Syndr. 2013;62(5):483-
6. 
21. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, 
efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 
2009;10(1):1-12. 
22. Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, et al. 
Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat 
redistribution and bone mass in HIV-infected adults: the Monarch randomized 
controlled trial. Int J STD AIDS. 2014;25(3):207-12. 
23. Chetchotisakd P. The CASTLE study: atazanavir/r versus lopinavir/r in 
antiretroviral-naive patients. Expert Rev Anti Infect Ther. 2009;7(7):801-5. 
24. Molina J-M, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, 
David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, 
each in combination with tenofovir and emtricitabine, for management of 
  
23 
antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of 
the CASTLE study. Lancet. 2010;372(9639):646-55. 
25. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P-M, et 
al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-
infected patients: 96-week analysis. AIDS. 2009;23(13):1679-88. 
26. Podzamczer D, Andrade‐Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P, 
et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with 
tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment‐naïve 
HIV‐1‐infected patients (the ARTEN study). HIV Med. 2011;12(6):374-82. 
27. Van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. 
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-
therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):e19. 
28. Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, et al. Lipid 
profiles for etravirine versus efavirenz in treatment-naive patients in the 
randomized, double-blind SENSE trial. Journal of Antimicrobial Chemotherapy. 
2012;67(3):685-90. 
29. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina J-M, et al. 
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 
week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289-300. 
30. Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung C-C, et al. Lipid 
Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected 
Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE 
Trials. Clin Infect Dis. 2014;59(3):425-34. 
31. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. 
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment 
of HIV-1: a randomized trial. Ann Intern Med. 2011;154(7):445-56. 
32. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, et al. 
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS. 
2014;28(10):1451-61. 
33. WHO. Policy Brief: Consolidated Guidelines on the Use of Antiretroviral Drugs 
For Treating and Preventing HIV Infection - What's New World Health Organisation. 
2015. 
34. Second-Line Study G. Ritonavir-boosted lopinavir plus nucleoside or 
nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus 
raltegravir for treatment of HIV-1 infection in adults with virological failure of a 
standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-
inferiority study. Lancet. 2013;381(9883):2091-9. 
35. Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Madruga JVR, et al. 
Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 
96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir 
Immune Defic Syndr. 2010;55(1):39-48. 
36. Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej 
S, Kantipong P, et al. A randomized comparison of second-line lopinavir/ritonavir 
monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing 
NNRTI regimens: the HIV STAR study. Antivir Ther. 2012;17(7):1351. 
37. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, et al. A 
96-week comparison of lopinavir-ritonavir combination therapy followed by 
  
24 
lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 
2008;198(2):234-40. 
38. Ciaffi L, Koulla-Shiro S, Sawadogo A, le Moing V, Eymard-Duvernay S, Izard S, 
et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected 
patients in Africa. AIDS. 2015;29(12):1473. 
39. Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. 
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J 
Med. 2014;371(3):234-47. 
40. Estill J, Ford N, Salazar-Vizcaya L, Haas AD, Blaser N, Habiyambere V, et al. 
The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 
2030: a mathematical modelling study. Lancet HIV. 2016;3(3):e132-e9. 
 
  
25 
 
Tables 
Table 1 – Baseline characteristics by on-study 2nd-line ART group  
 
Variable All  TDF taNRTI 
(AZT/d4T) 
TDF + taNRTI  RAL  
Number of patients 
(n) 
454 107 37 63 247 
Demographic  
Sex  
Male (n, %) 
Female (n, %)  
 
245 (54%) 
209 (46%)  
 
71 (66.4%)  
36 (33.6%)  
 
18 (48.7%) 
19 (50%)  
 
25 (39.7%)  
38 (60.3%)  
 
131 (53.0%)  
116 (46.0%)  
Age  38.6 (32.5-
44.4) 
38.9 (32.9-
45.7) 
34.7 (32.4- 
40.8)  
38.0 (34.6-
42.8)  
38.8 (32.3-
44.5)  
Ethnicity  
Caucasian (n, %) 
 
Asian (n, %) 
 
Hispanic (n, %) 
 
African (n, %)  
 
 
33 (7.3%) 
 
189 (41.6%) 
 
54 (11.9%) 
 
178 (39.2%) 
 
2 (1.9%)  
 
62 (57.9%) 
 
9 (8.4%) 
 
34 (31.8%)  
 
 0 (0%) 
 
5 (13.5%) 
 
2 (5.4%) 
 
30 (81.1%)  
 
10 (15.9%) 
 
16 (25.4%)  
 
10 (15.9%)  
 
27 (42.9%) 
 
21 (8.5%) 
 
106 (42.9%) 
 
33 (13.4%) 
 
87 (35.2%)  
 
Clinical       
Weight (kg)  63  (55.5-73)  61.4 (55.0-
70.7) 
61.0 (55.5-
68)  
64.6 (56.8-
81.5)  
63.3 (55-
71.6)  
BMI (kg/m2)  23.2 (20.6-
26.5) 
23.1 (19.6-
25.6)  
22.5 (20.3-
25.9)  
24.5 (21.3-
28.2)  
23.4 (20.7-
26.3)  
BP (mmHg) 
Systolic 
 
 
Diastolic 
 
117 (108-
126)  
 
74 (70-80)  
 
120 (108-
132)  
 
78 (70-85)  
 
110 (100-
118) 
 
70 (67-80) 
 
120 (111-
123) 
 
75 (70-82)  
 
115 (107-
125)  
 
73 (70-80)  
Waist/Hip Ratio 0.89 (0.84-
0.95)  
0.89 (0.84-
0.94)  
0.91 (0.85-
0.95) 
0.87 (0.83-
0.95)  
0.90 (0.84-
0.95)  
Metabolic markers (fasting) 
Total Cholesterol 
(mmol/L) 
4.4 (3.8-5.1) 4.5 (3.9-5.2)  4.5 (3.5-5.1)  4.3 (3.5-5.0)  4.4 (3.8-5.1)  
Triglycerides 
(mmol/L) 
1.3 (0.9-1.9) 1.3 (0.9-2.0) 1.4 (1.0-1.9) 1.2 (0.9-1.8) 1.3 (0.9-1.9) 
HDL-C (mmol/L) 1.1 (0.9-1.4) 1.1 (0.9-1.3) 1.2 (1.0-1.5) 1.1 (0.9-1.5)  1.1 (0.9-1.4)  
LDL-C (mmol/L) 2.5 (1.9-3.0) 2.6 (2.2-3.2)  1.7 (1.4-2.2)  2.4 (1.9-3.1)  2.5 (1.9-3.0) 
TC/HDL Ratio  3.9 (3.2-4.8) 4.2 (3.5-5) 3.8 (3.2-4.3)  3.4 (2.9-4.2)  3.9 (3.2-4.9) 
Glucose (mmol/L) 4.8 (4.4-5.2)  4.8 (4.4-5.2) 4.7 (4.5-5.3)  4.8 (4.3-5.1)  4.8 (4.4-5.3) 
Insulin (mU/L) 7.9 (5.0-14.0)  7.0 (4.0-14.0)  7.2 (4.50-
13.00)  
7.5 (5.4-12.3)  8 (5-14.1)  
HOMA-IR  1.6 (1.0-3.1) 1.6 (0.9-3.2)  1.6 (0.9-2.9) 1.5 (1.1-2.8)  1.7 (1.0-3.2)  
HIV and cART history  
Duration of 
infection (years) 
6.1 (3.7-8.7)  6.5 (4.5-8.8)  2.7 (2.0-5.1)  7.0 (4.2-9.9)  6.2 (3.7-8.9)  
HIV disease stage       
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Category A 
 
Category B 
 
Category C  
172 (37.9%) 
 
70 (15.4%) 
 
212 (46.7%) 
43(40.2%) 
 
11 (10.3%) 
 
53 (49.5%)  
10 (27.0%) 
 
9 (24.3%) 
 
18 (48.7%)  
31 (49.2%) 
 
8 (12.7%) 
 
24 (38.1%)  
88 (35.6%)  
 
42 (17.0%)  
 
117 (47.4%)  
CD4 Count (cells/μL) 
 
199 (101-
296)  
207 (108-
293)  
64 (41-200)  223 (135-
315) 
202 (109-
311)  
CD8 Count (cells/μL) 800 (533.5-
1095)  
849 (567-
1135) 
536 (310-
844) 
721 (478-
948) 
812 (569-
1126)  
Log 10 HIV RNA level 
(copies/mL)   
4.2 (3.6-4.8)  4.4 (3.8-5.0) 4.5 (3.9-5.0) 4.0 (3.5-4.4) 4.2 (3.6-4.8)  
cART duration pre-
randomisation 
(years)   
3.5 (2.0-5.7)  3.4 (2.1-5.4)  2.2 (1.5-4.3)  3.8 (2.1-6.0)  3.7 (2.2-5.8)  
Other relevant risk factors/medical history  
Alcohol 
consumption 
2 drinks a day or less 
 
More than 2 drinks a 
day  
 
 
442 (97.4%) 
 
 
12 (2.6%)  
 
 
106 (99.1%) 
 
 
1 (0.9%) 
 
 
36 (97.3%) 
 
 
1 (2.7%) 
 
 
58 (92.1%) 
 
 
5 (7.9%) 
 
 
242 (98.0%) 
 
 
5 (2.0%)  
Smoking  
Currently (n, %) 
 
Recent (n, %) 
 
Past (n, %) 
 
Never (n, %)  
 
70 (15.4%) 
 
19 (4.2%) 
 
75 (16.5%) 
 
290 (63.9%)  
 
19 (17.8%) 
 
5 (4.7%) 
 
15 (14.0%) 
 
68 (63.6%)  
 
3 (8.1%) 
 
0  
 
10 (27.0%) 
 
24 (64.9%) 
 
12 (19.1%) 
 
0  
 
10 (15.9%) 
 
41 (65.1%)  
 
36 (14.6%) 
 
14 (5.7%) 
 
40 (16.2%) 
 
157 (63.6%)  
Use of lipid-lowering 
drugs 
No (n, %) 
 
Yes (n,%)  
 
 
382 (84.1%) 
 
72 (15.9%)  
 
 
89 (83.2%) 
 
18 (16.8%) 
 
 
36 (97.3%) 
 
1 (2.7%) 
 
 
59 (93.7%) 
 
4 (6.4%) 
 
 
198 (80.2%)  
 
49 (19.8%)  
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Table 2 - Baseline characteristics by 1L to 2L treatment switch group  
 
Variable All  taNRTI 
(AZT/d4T)  
To  
TDF  
taNRTI  
to  
taNRTI + 
TDF  
taNRTI  
to  
RAL  
TDF  
To  
taNRTI  
TDF  
To  
RAL  
Number of patients 
(n) 
454 100 (22.0%) 52 (11.5%) 200 (44.1%) 33 (7.3%) 47 (10.4%) 
Demographics 
Sex 
Male 
 
Female  
 
245 (54%) 
 
209 (46%)  
 
66 (66%) 
 
34 (34%)  
 
20 (38.5%) 
 
32 (61.5%)  
 
107 (53.5%)  
 
93 (46.5%)  
 
17 (51.5%) 
 
16 (48.5%) 
 
24 (51.1%) 
 
23 (48.9%)   
Age  38.6 (32.5-
44.4) 
39.6 (33.2-
45.8)  
38.0 (34.6-
43.2) 
39.0 (32.2-
44.5) 
35.0 (33.1-
40.8) 
37.8 (32.3-
44.5)  
Ethnicity  
 
Caucasian 
 
Asian 
 
Hispanic 
 
African 
 
 
33 (7.3%) 
 
189 (41.6%) 
 
54 (11.9%) 
 
178 (39.2%) 
 
 
2 (2.0%) 
 
57 (57.0%) 
 
9 (9.0%)  
 
32 (32.0%) 
 
 
8 (15.4%) 
 
14 (26.9%) 
 
10 (19.2%) 
 
20 (38.5%)  
 
 
20 (10.0%) 
 
83 (41.5%) 
 
30 (15.0%) 
 
67 (33.5%) 
 
 
0 (0%)  
 
5 (15.2%) 
 
0 (0%) 
 
28 (84.9%) 
 
 
1 (2.1%) 
 
23 (48.9%) 
 
3 (6.4%)  
 
20 (42.6%)  
Clinical  
Weight (kg)  63  (55.5-73)  61.7 (54.5-
70.4) 
64.8 (56.8-
79.5) 
64.6 (55.7-
74.1) 
60.4 (55-67) 60 (54-65.4)  
BMI (kg/m2) 23.2 (20.6-
26.5)  
22.9 (19.6-
25.5)  
25.1 (21.1-
28.3)  
23.4 (21.0-
27.4)  
21.1 (20.3-
25.2) 
22.9 (19.7-
24.4) 
BP (mmHg) 
Systolic 
 
 
Diastolic 
 
117 (108-
126)  
 
74 (70-80)  
 
 
119.5 (107-
132) 
 
78 (70-85.5)  
 
120 (112-
123)  
 
75 (70-81).5  
 
117.5 (109-
127) 
 
75 (70-80) 
 
110 (100-
118) 
 
70 (70-80) 
 
110 (100-
115)  
 
70 (70-80) 
Waist/Hip Ratio 0.89 (0.84-
0.95)  
0.89 (0.84-
0.94) 
0.90 (0.83-
0.96)  
0.89 (0.84-
0.95)  
0.91 (0.85-
0.95) 
0.90 (0.84-
0.97)  
Metabolic markers (fasting) 
Total Cholesterol 
(mmol/L) 
4.4 (3.8-5.1) 4.5 (3.9-5.2) 4.3 (3.7-5.3)  4.3 (3.8-5.2)  4.5 (3.7-5.1) 4.5 (3.9-4.9)  
Triglycerides 
(mmol/L) 
1.3 (0.9-1.9) 1.4 (0.9-2.0) 1.2 (0.9-1.9) 1.3 (0.9-2.0) 1.4 (1.0-1.9) 1.4 (0.9-1.9) 
HDL-C (mmol/L) 1.1 (0.9-1.4) 
 
1.1 (0.9-1.4) 1.2 (1.0-1.6) 1.1 (0.9-1.4) 1.2 (1.0-1.5) 1.1 (0.9-1.3)  
LDL-C (mmol/L) 2.5 (1.9-3.0) 
 
2.7 (2.2-3.2) 2.4 (1.9-3.2) 2.5 (2.0-3.0) 1.7 (1.3-2.1) 2.4 (1.6-2.8) 
TC/HDL Ratio  
 
3.9 (3.2-4.8) 4.2 (3.5-5.0) 3.4 (2.8-4.1) 3.9 (3.1-4.9) 3.8 (3.2-4.3) 4 (3.4-4.7) 
Glucose (mmol/L) 
 
4.8 (4.4-5.2)  4.8  (4.4-5.2) 4.7 (4.3-5.1) 4.8 (4.4-5.3) 4.9 (4.5-5.4) 4.9 (4.7-5.4) 
Insulin (mU/L) 7.9 (5.0-
14.0)  
7.0 (4.7-14.0 
) 
7.9 (5.8-
13.0) 
8.0 (5.0-
14.5) 
6.1 (3.5-
12.5) 
7.5 (4.0-12)  
  
28 
HOMA-IR  1.6 (1.0-3.1) 1.6 (0.9-3.1) 1.6 (1.1-3.0) 1.7 (1.0-3.3) 1.4 (0.8-2.8) 1.6 (0.9-3.0) 
HIV & cART History  
Duration of 
infection (years) 
6.1 (3.7-8.7)  6.6 (4.6-8.9) 7.0 (4.4-9.4) 6.5 (4.0-9.8) 3.1 (2.0-5.1) 4.6 (2.8-7.4)  
HIV disease stage  
Category A 
 
Category B 
 
Category C  
 
172 (37.9%) 
 
70 (15.4%) 
 
212 (46.7%) 
 
42 (42%)  
 
10 (10%) 
 
48 (48%) 
 
29 (55.8%) 
 
7 (13.5%) 
 
16 (30.8%) 
 
74 (37%)  
 
31 (15.5%)  
 
95 (47.5%) 
 
8 (24.2%) 
 
9 (27.3%)  
 
16 (48.5%) 
 
14 (29.8%) 
 
11 (23.4%) 
 
22 (46.8%)  
CD4 Count 
(cells/μL) 
199 (101-
296)  
207 (115-
291) 
253 (177-
324) 
218 (119-
323) 
62 (35-176) 144 (56-
243) 
CD8 Count 
(cells/μL) 
800 (533.5-
1095)  
853.5 (600-
1138) 
773 (566-
971) 
820 (593-
1141) 
495 (300-
778) 
723 (463-
1092)  
Log 10 HIV RNA 
level (copies/mL) 
4.2 (3.6-4.8)  4.4 (3.7-5.0) 3.9 (3.3-4.3) 4.2 (3.5-4.7) 4.5 (3.9-5.1) 4.4 (3.7-5.3) 
cART duration pre-
randomisation  
3.5 (2.0-5.7)  3.4 (2.1-5.3) 4.0 (2.2-6.0) 3.9 (2.5-5.9) 2.2 (1.5-4.3) 3.3 (1.3-5.0) 
Other Relevant Risk Factors/Medical History  
Alcohol 
consumption (per 
day) 
≤ 2 drinks 
 
>2 drinks  
 
 
 
442 (97.4%) 
 
12 (2.6%)  
 
 
 
99 (99%) 
 
1 (1%) 
 
 
 
50 (96.2%) 
 
2 (3.9%) 
 
 
 
195 (97.5%) 
 
5 (2.5%) 
 
 
 
32 (97%)  
 
1 (3%) 
 
 
 
47 (100%) 
 
0 (0%)  
Smoking  
Currently 
 
Recent 
 
Past  
 
Never 
 
70 (15.4%) 
 
19 (4.2%) 
 
75 (16.5%) 
 
290 (63.9%)  
 
19 (19%)  
 
5 (5%)  
 
14 (14%) 
 
62 (62%)  
 
10 (19.2%)  
 
0 (0%) 
 
8 (15.4%)  
 
384 (65.4%)  
 
32 (16.0%)  
 
12 (6.0%) 
 
33 (16.5%)  
 
123 (61.5%)  
 
3 (9.1%)  
 
0 (0%) 
 
10 (30.3%)  
 
20 (60.6%)  
 
4 (8.5%)  
 
2 (4.3%)  
 
7 (14.9%)  
 
34 (72.3%)  
Lipid lowering 
drugs 
No 
 
Yes 
 
 
382 (84.1%) 
 
72 (15.9%)  
 
 
83 (83%)  
 
17 (17%) 
 
 
48 (92.3%) 
 
4 (7.7%)  
 
 
159 (79.5%) 
 
41 (20.5%) 
 
 
32 (97.0%)  
 
1 (3.0%)  
 
 
39 (83%) 
 
8 (17%)  
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Figure 1: Participant disposition  
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Figure 2:  Adjusted mean metabolic change, by on-study 2nd line ART 
Group  
 
 
  
32 
Figure 3 : Adjusted mean metabolic change, by 1st-line to 2nd-line switch 
group  
 
 
 
